HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.0
  1. Home
  2. /Reaction

p-Toluenesulfonic acid → (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4,4-difluoro-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide

HRID 19313
Notes
Print preview

Reaction equation

HRID 19313 reaction equation
CC1(C)[O:6][C@H:5]([CH2:7][N:8]2[CH:12]=[CH:11][C:10]([NH:13][C:14](=[O:35])[C@@H:15]([N:21]3[CH2:25][C:24]([O:26][C:27]4[CH:32]=[CH:31][CH:30]=[CH:29][C:28]=4[Cl:33])=[CH:23][C:22]3=[O:34])[CH2:16][C:17]([F:20])([F:19])[CH3:18])=[N:9]2)[CH2:4][O:3]1.C1(C)C=CC(S(O)(=O)=O)=CC=1>CO>[OH:6][C@@H:5]([CH2:4][OH:3])[CH2:7][N:8]1[CH:12]=[CH:11][C:10]([NH:13][C:14](=[O:35])[C@@H:15]([N:21]2[CH2:25][C:24]([O:26][C:27]3[CH:32]=[CH:31][CH:30]=[CH:29][C:28]=3[Cl:33])=[CH:23][C:22]2=[O:34])[CH2:16][C:17]([F:19])([F:20])[CH3:18])=[N:9]1
ParticipantsConditionsProcedureWorkupSources & evidenceReaction notes

Participants

4

Reactant 2

HCID 6101p-Toluenesulfonic acidHCID 66898996HCID 66898996, compound

Product 1

HCID 57920051(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4,4-difluoro-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amideYield 82.5%

Reagents, catalysts & solvents 1

HCID 887MethanolSolvent

Conditions

Temperature
25 °C

Procedure

In a round bottom flask was placed (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4,4-difluoro-pentanoic acid [1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-1H-pyrazol-3-yl]-amide (70 mg, 0.13 mmol), methanol (3 mL) and p-toluenesulfonic acid (5 mg, 0.15 mmol). The mixture was stirred at 25° C. for 24 h and then concentrated in vacuo and dissolved in ethyl acetate and concentrated in vacuo with silica gel (1 g). Purification by Biotage flash chromatography (AnaLogix SF15-12 g column, 100% ethyl acetate to 10% methanol/ethyl acetate) afforded (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4,4-difluoro-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide (52 mg, 82%) as a white foam: HR-ES-MS m/z calculated for C21H23N4O5ClF2 [M+H]+ 485.1398, observed 485.1396; 1H NMR (300 MHz, DMSO-d6) δ ppm 1.66 (t, J=19.3 Hz, 3H), 3.21-3.33 (m, 2H), 3.69-3.81 (m, 1H), 3.87 (dd, J=13.6, 7.5 Hz, 1H), 4.01-4.17 (m, 1H), 4.30 (d, J=18.4 Hz, 1H), 4.47 (d, J=18.4 Hz, 1H), 4.72 (t, J=5.6 Hz, 1H), 4.81 (s, 1H), 4.95 (d, J=5.1 Hz, 1H), 5.12 (dd, J=9.1, 5.1 Hz, 1H), 6.42 (d, J=2.1 Hz, 1H), 7.32-7.41 (m, 1H), 7.42-7.53 (m, 2H), 7.55 (dd, J=2.1 Hz, 1H), 7.66 (d, J=7.8 Hz, 1H), 10.85 (s, 1H).

Workup

  1. customIn a round bottom flask was placed
  2. concentrationconcentrated in vacuo
  3. dissolutiondissolved in ethyl acetate
  4. concentrationconcentrated in vacuo with silica gel (1 g)
  5. customPurification by Biotage flash chromatography (AnaLogix SF15-12 g column, 100% ethyl acetate to 10% methanol/ethyl acetate)

Sources & evidence

ORD record
ord-01d8eb3a996f45d1a3aea509de49bc9b
Source dataset
uspto-grants-2010_06
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US07741327B2

Reaction notes

Loading…

On this pageParticipantsConditionsProcedureWorkupSources & evidenceReaction notes